JOSÉ ÁNGEL
HERNÁNDEZ RIVAS
Profesor asociado de Ciencias de la Salud
![Foto de JOSÉ ÁNGEL](/img/nophoto.png)
![Foto de Hospital Clinico Universitario de Valencia](/img/noimage_org.png)
Hospital Clinico Universitario de Valencia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clinico Universitario de Valencia (18)
2024
-
Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)
eClinicalMedicine, Vol. 73
-
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
Frontiers in Oncology, Vol. 14
2023
-
Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients
Viruses, Vol. 15, Núm. 10
-
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
Bone Marrow Transplantation, Vol. 58, Núm. 5, pp. 567-580
2022
-
Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients
Annals of Hematology, Vol. 101, Núm. 9, pp. 2053-2067
-
Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial
Journal of Clinical Medicine, Vol. 11, Núm. 19
-
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
International Journal of Hematology, Vol. 116, Núm. 3, pp. 381-392
-
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
Journal of hematology & oncology, Vol. 15, Núm. 1, pp. 54
-
SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group
American Journal of Hematology, Vol. 97, Núm. 1, pp. 30-42
-
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients
Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550
2021
-
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 12, pp. e985-e999
-
Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively
Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1
2020
-
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country
Experimental Hematology and Oncology
2019
-
Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia
Mediterranean Journal of Hematology and Infectious Diseases, Vol. 11
2017
-
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
Haematologica, Vol. 102, Núm. 1, pp. 103-109
-
Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia
Medicina Clinica, Vol. 148, Núm. 8, pp. 381.e1-381.e9
2016
-
Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera
British Journal of Haematology, Vol. 172, Núm. 5, pp. 786-793